STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENTA
  4. [8-K] ENANTA PHARMACEUTICALS INC Reports Material Event

Enanta (NASDAQ: ENTA) has Paxlovid-related patent invalidated on appeal

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Enanta Pharmaceuticals, Inc. reported that the United States Court of Appeals for the Federal Circuit has affirmed a prior summary judgment ruling in its patent case against Pfizer Inc. The Federal Circuit ruled that the claims of Enanta’s U.S. Patent No. 11,358,953, related to Pfizer’s COVID-19 antiviral Paxlovid, are invalid, effectively upholding the December 2024 decision from the U.S. District Court for the District of Massachusetts.

Positive

  • None.

Negative

  • None.

Insights

Federal Circuit invalidates Enanta patent in Paxlovid case.

The decision by the United States Court of Appeals for the Federal Circuit leaves Enanta without enforceable claims under U.S. Patent No. 11,358,953 in its suit against Pfizer over Paxlovid. The appellate court affirmed the prior December 2024 summary judgment ruling.

This outcome removes the possibility of relief in this case based on the ’953 Patent and finalizes the validity dispute at the appellate level. The filing does not describe any alternative patents or ongoing related actions, so its focus remains on this specific asset and litigation.

Investors may look to future company communications and periodic reports for any discussion of the broader business implications of this ruling, including how the loss of the ’953 Patent claims factors into Enanta’s overall intellectual property and litigation strategy.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
ENANTA PHARMACEUTICALS INC false 0001177648 0001177648 2026-06-23 2026-06-23
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2026

 

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-35839   04-3205099
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

4 Kingsbury Avenue  
Watertown, Massachusetts   02472
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 


Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.01 per share   ENTA   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01 Other Events.

As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the “’953 Patent”) in the manufacture, use, and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). On June 23, 2026, the Federal Circuit affirmed the December 2024 summary judgment decision of the United States District Court for the District of Massachusetts and ruled that the claims of the ’953 Patent were invalid.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ENANTA PHARMACEUTICALS, INC.
Date: June 23, 2026     By:  

/s/ Jay R. Luly, Ph.D.

      Jay R. Luly, Ph.D.
President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents